Intuitive Surgical Earnings Reports

Intuitive Surgical delivered a strong Q3 2025 with 23% revenue growth, higher da Vinci and Ion procedure volumes, and a significant increase in da Vinci 5 system placements.

Intuitive Surgical delivered a robust second quarter in 2025, with total revenue increasing by 21% year-over-year to $2.44 billion. GAAP net income rose to $658 million, and non-GAAP net income reached $798 million. The company saw a 17% growth in worldwide da Vinci procedures and placed 395 da Vinci surgical systems, including 180 da Vinci 5 systems, contributing to a 14% increase in its installed base.

Intuitive Surgical delivered a robust quarter with 19% revenue growth and a solid increase in net income. The company saw higher da Vinci system placements, especially the da Vinci 5, and increased procedure volumes across its platforms.

Intuitive Surgical announced strong financial results for the fourth quarter of 2024, with revenue increasing by 25% compared to the fourth quarter of 2023. The company placed 493 da Vinci surgical systems during the quarter, including 174 da Vinci 5 systems. GAAP net income attributable to Intuitive Surgical was $686 million, or $1.88 per diluted share, while non-GAAP net income was $805 million, or $2.21 per diluted share.

Intuitive Surgical announced strong Q3 2024 results, with revenue reaching $2.04 billion, a 17% increase compared to Q3 2023. The company saw growth in da Vinci procedures and an increase in the installed base of systems, placing 379 da Vinci surgical systems during the quarter.

Intuitive Surgical reported a strong second quarter with revenue reaching $2.01 billion, a 14% increase year-over-year. The company saw growth in da Vinci procedures and system placements, with a notable increase in the installed base of da Vinci surgical systems. GAAP net income was $527 million, or $1.46 per diluted share, while non-GAAP net income was $641 million, or $1.78 per diluted share.

Intuitive Surgical announced its Q1 2024 financial results, highlighted by an 11% increase in revenue to $1.89 billion compared to Q1 2023. The company's GAAP net income attributable to Intuitive Surgical was $545 million, or $1.51 per diluted share. The growth was fueled by increased da Vinci procedure volume and expansion of the installed base.

Intuitive Surgical announced strong Q4 2023 results, with revenue increasing by 17% year-over-year to $1.93 billion. The company saw growth in da Vinci procedure volume and an increase in the installed base of systems. GAAP net income attributable to Intuitive Surgical was $606 million, or $1.69 per diluted share, while non-GAAP net income was $574 million, or $1.60 per diluted share.

Intuitive Surgical announced strong Q3 2023 results, with revenue increasing by 12% to $1.74 billion. The company's GAAP net income rose to $416 million, or $1.16 per diluted share, while non-GAAP net income reached $524 million, or $1.46 per diluted share. Growth was driven by increased da Vinci procedure volume and expansion of the installed base.

Intuitive Surgical announced strong Q2 2023 results, with revenue reaching $1.76 billion, a 15% increase compared to Q2 2022. The company's growth was fueled by a rise in da Vinci procedures and an expansion of its installed base. GAAP net income was $421 million, or $1.18 per diluted share, while non-GAAP net income was $507 million, or $1.42 per diluted share.

Intuitive Surgical announced a 14% increase in revenue to $1.70 billion for Q1 2023, driven by growth in da Vinci procedure volume. The company placed 312 da Vinci Surgical Systems during the quarter and grew its installed base to 7,779 systems. GAAP net income was $355 million, or $1.00 per diluted share, while non-GAAP net income was $437 million, or $1.23 per diluted share.

Intuitive Surgical announced a 7% increase in revenue to $1.66 billion for Q4 2022, driven by da Vinci procedure volume growth, but system placements declined. GAAP net income decreased to $325 million, or $0.91 per diluted share, while non-GAAP net income was $439 million, or $1.23 per diluted share. The company repurchased $1 billion of common stock during the quarter and ended with $6.74 billion in cash, cash equivalents, and investments.

Intuitive Surgical announced its Q3 2022 financial results, with revenue increasing by 11% to $1.56 billion compared to Q3 2021. The growth was driven by increased da Vinci procedure volume, although system placements saw a decline. GAAP net income attributable to Intuitive Surgical was $324 million, or $0.90 per diluted share, while non-GAAP net income was $429 million, or $1.19 per diluted share.

Intuitive Surgical announced a 4% increase in revenue to $1.52 billion, driven by da Vinci procedure growth, but system placements declined. GAAP net income was $308 million, or $0.85 per diluted share, while non-GAAP net income was $415 million, or $1.14 per diluted share. The company repurchased $500 million of common stock and increased the repurchase program to $3.5 billion.

Intuitive Surgical announced a 15% increase in revenue to $1.49 billion for Q1 2022, driven by growth in da Vinci procedure volume and system placements. GAAP net income was $366 million, or $1.00 per diluted share, while non-GAAP net income was $413 million, or $1.13 per diluted share. The company's installed base grew to 6,920 systems.

Intuitive Surgical announced its Q4 2021 financial results, with revenue reaching $1.55 billion, a 17% increase compared to Q4 2020. The company shipped 385 da Vinci Surgical Systems, and the installed base grew to 6,730 systems. GAAP net income was $381 million, or $1.04 per diluted share, while non-GAAP net income was $477 million, or $1.30 per diluted share.

Intuitive Surgical announced strong financial results for Q3 2021, with revenue increasing by 30% to $1.40 billion compared to Q3 2020. The growth was driven by higher da Vinci system placements and procedure volume. GAAP net income was $381 million, or $1.04 per diluted share, while non-GAAP net income was $435 million, or $1.19 per diluted share.

Intuitive Surgical announced strong second-quarter results, with revenue increasing by 72% year-over-year to $1.46 billion. The growth was primarily driven by a surge in da Vinci procedures and system placements, indicating a recovery from the pandemic-related disruptions in the previous year. The company's GAAP net income also saw a substantial increase, reaching $517 million, or $4.25 per diluted share.

Intuitive Surgical announced strong first-quarter results, with revenue reaching $1.29 billion, an 18% increase compared to the first quarter of 2020. The growth was driven by increased da Vinci procedures and system placements. GAAP net income was $426 million, or $3.51 per diluted share.

Intuitive Surgical announced Q4 2020 financial results, with revenue increasing by 4% to $1.33 billion. The company's da Vinci Surgical System installed base grew by 7% to 5,989 systems. GAAP net income was $365 million, or $3.02 per diluted share, while non-GAAP net income was $434 million, or $3.58 per diluted share.

Intuitive Surgical reported a decrease in revenue and system placements due to the COVID-19 pandemic, while da Vinci procedures experienced a partial recovery. The company's revenue decreased by 4% compared to the third quarter of 2019. Despite the challenges, the installed base of da Vinci systems continued to grow.

Intuitive Surgical announced a decrease in revenue, system placements, and procedures due to the COVID-19 pandemic. The company's Q2 revenue was $852 million, a 22% decrease compared to Q2 2019. GAAP net income was $68 million, or $0.57 per diluted share, compared to $318 million, or $2.67 per diluted share, in the second quarter of 2019.

Intuitive Surgical announced Q1 2020 financial results, with revenue growing 13% year-over-year to $1.1 billion. The company shipped 237 da Vinci Surgical Systems, a 1% increase compared to Q1 2019. GAAP net income was $314 million, or $2.62 per diluted share, while non-GAAP net income was $323 million, or $2.69 per diluted share.

Intuitive Surgical announced strong Q4 2019 results, with revenue up 22% year-over-year to $1.28 billion. The company saw growth in da Vinci procedures and system placements, driving increased revenue. GAAP net income was $358 million, or $2.99 per diluted share, while non-GAAP net income was $417 million, or $3.48 per diluted share.